AMGEN INC (AMGN)       253.65  -1.23 (-0.48%)

AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023,...

Horizon, Opiant stock fall on report Elizabeth Warren concerned about pharma deals

Horizon Pharmaceuticals (HZNP) dropped on a report that Sen. Elizabeth Warrenhas concerns about Amgen's (AMGN) plan to buy Horizon Therapeutics (HZNP) and Indivior plan to acquire Opiant

Horizon, Opiant stock fall amid Elizabeth Warren concerned about pharma deals

Horizon Pharmaceuticals (HZNP) dropped on a report that Sen. Elizabeth Warrenhas concerns about Amgens (AMGN) plan to buy Horizon Therapeutics (HZNP) and Indivior plan to acquire Opiant

2 Top Biotech Stocks to Buy for the Long Haul

Developing new products will be key to the success of both of these biotech leaders.

Noteworthy Wednesday Option Activity: MS, AMGN, JPM

Dogs of the Dow 2023: 5 Dividend Stocks for Income Investors

The 2023 Dogs of the Dow feature several stocks investors should consider for their income portfolios. Here are the top five picks.

2 Top Passive-Income Stocks to Own in 2023

These dividend stocks can deliver both downside protection and capital appreciation.

3 Dividend Stocks You Can Safely Hold for Years

Look for the top companies in businesses the world perpetually needs.

First Week of AMGN March 17th Options Trading

See Which Of The Latest 13F Filers Holds Amgen

Obesity Treatments Catch Drugmakers’ Eyes as Sales Seen Soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Amgen, AstraZeneca's asthma therapy Tezspire's self-administration gets approval in EU

A panel of the European Medicine Agency ((EMA)) issued a positive opinion on a self-administration option of Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire.The decision of...

Dow Movers: UNH, DIS

Flour Made From Food Waste Is Coming for Your Cookies

The Supplant Co. has trademarked a method of turning discarded oat hulls into high-protein starch.

The Dogs of the Dow Worked Last Year, But This Strategy Could Make You More Money in 2023

Meet the Dogs of the S&P.

5 Top Pharma Stocks of 2022 to Buy for the Long Haul

The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.

AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET

/PRNewswire/ -- Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden...

Humira Competitors Have CVS Wrestling With Complex Calculations

CVS Health Corp., the largest prescription benefits provider in the US, is still deciding on its approach to covering one of the world’s best-selling drugs, Humira, as a competing version is set to hit the market at the end of this month.

Dow Analyst Moves: AMGN

3 Top U.S. Stocks to Watch in January

Considering their potential, all three stocks look like good opportunities today.

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

/PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 J.P. Morgan Healthcare Conference at 6:45 p.m. ET on Monday, January 9, 2023. Robert A. Bradway,...

Could the Dow Jones Keep Outperforming the Nasdaq Composite in 2023?

The Dow crushed the Nasdaq in 2022, but that's no guarantee of a lasting trend.

Meet the 2023 Dogs of the Dow

After a tumultuous year, this simple strategy that outperformed sagging markets might be just what you're looking for.

2 Unstoppable Dividend Growth Stocks to Buy in 2023 and Beyond

Nothing is more reassuring to an income investor than a boost to the dividend.

The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock

Investors are closely watching two key spaces that could spark Lilly stock.